B+
Bull case
20%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
SABS
SAB BiotherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$3.25
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$1.75
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+59.8
Score
AI commentary
Clinical-program news is modestly constructive because of the PRISE-hATG grant, manufacturing agreement, and previously reported SAFEGUARD progress, but the post-earnings evidence is incomplete. The RankAlpha anchor was $3.85 on August 6 versus a live quote of $3.90 on August 8, a muted move that cannot be causally attributed to the print. Social context, options data, short interest, and reliable analyst reaction were unavailable.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-06eventQ2 2026 post-earnings evidence remains unresolvedMedium impact
The Q2 2026 10-Q was filed on August 6, but the available excerpt is truncated; no validated EPS/revenue surprise, guidance change, analyst revision, or transcript-based driver was confirmed. Treat the post-print signal as unresolved rather than bullish or bearish. [#SEC-10Q-2026-08-06] [#PR-EARNINGS-2026-07-30]
2026-12-31eventPRISE-hATG clinical-program expansionHigh impact
Breakthrough T1D awarded a grant supporting the investigator-led PRISE-hATG study of SAB-142, which SAB BIO will co-fund. The study extends evaluation beyond the earliest post-diagnosis window, but no readout date was confirmed. [#8-K-2026-07-07] [#IR-2026-07-07]
2026-12-31catalystSAFEGUARD enrollment completion checkpointHigh impact
SAB BIO previously stated that enrollment in the registrational Phase 2b SAFEGUARD study was on track for completion by year-end 2026. Any delay or confirmation would be material, but the latest post-earnings enrollment update was not verified. [#IR-2026-05-12]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology